Regenerative medicine company Mesoblast has been hit with a second class action for allegedly misleading shareholders about it Remestemcel-L treatment for COVID-19 complications.

Subscribe to Lawyerly to access this article.

Already a subscriber?
Lost your password?

For information on rights and reprints, contact subscriptions@lawyerly.com.au